Form 4: BIO-TECHNE CEO Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report 5 November 2025 4:46 PM

BIO-TECHNE Corp's CEO, Kim Kelderman, reported the disposition of 2,303 common shares at $62.57 each to cover tax withholding obligations.

Summary

Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, reported a transaction on November 3, 2025.
Kelderman disposed of 2,303 shares of BIO-TECHNE common stock at a price of $62.57 per share.
This disposition was made to satisfy tax withholding obligations, indicated by transaction code 'F'.
Following this transaction, Kelderman directly beneficially owns 48,665 shares of common stock.
Kelderman also holds various derivative securities, including stock options and performance restricted stock units, with different vesting schedules and exercise prices, which were not part of this specific transaction.

Sentiment

Score: 5

Explanation: The transaction is a routine disposition of shares to cover tax withholding obligations, which is a neutral event. While it reduces direct ownership, it is not indicative of a change in sentiment towards the company's prospects or a strategic divestment.

Negatives

The CEO disposed of 2,303 shares of common stock, which, while for tax purposes, reduces their direct ownership in the company.

Future Outlook

Industry Context

Related Party Transactions

Disposition of common stock by CEO Kim Kelderman to BIO-TECHNE Corp to satisfy tax withholding obligations.

Stakeholder Impact

Shareholders: A minor reduction in direct insider ownership, though for a routine tax purpose, which typically has minimal impact on investor perception.

Next Steps

Various tranches of stock options are scheduled to vest on specific dates between August 2024 and August 2028.
Restricted Stock Units are scheduled to vest on specific dates between August 2026 and August 2028.
Performance Restricted Stock Units and Performance Stock Options are scheduled to vest on August 15, 2026, August 15, 2027, and August 15, 2028, contingent upon the achievement of certain performance goals.

Key Dates

Date	Description
08/15/2024	Vesting of 7,348 stock options with an exercise price of $84.61.
11/01/2024	Vesting of 9,563 stock options with an exercise price of $52.83.
02/01/2025	Vesting of 12,973 stock options with an exercise price of $68.54.
08/15/2025	Vesting of 7,348 stock options with an exercise price of $84.61 and 17,265 stock options with an exercise price of $74.91.
11/01/2025	Vesting of 9,563 stock options with an exercise price of $52.83.
11/03/2025	Date of reported transaction (disposition of common stock).
11/05/2025	Signature date of the reporting person's attorney-in-fact.
02/01/2026	Vesting of 12,972 stock options with an exercise price of $68.54.
08/15/2026	Vesting of performance restricted stock units (8,873 shares) if performance goals are achieved; vesting of 7,347 stock options ($84.61 exercise price); vesting of 8,543 restricted stock units; vesting of 11,785 restricted stock units; vesting of 30,147 stock options ($53.6 exercise price).
11/01/2026	Vesting of 9,563 stock options with an exercise price of $52.83.
02/01/2027	Vesting of 12,973 stock options with an exercise price of $68.54.
08/05/2027	Expiration of stock options with an exercise price of $66.97.
08/15/2027	Vesting of performance restricted stock units (51,261 shares) if performance goals are achieved; vesting of 7,348 stock options ($84.61 exercise price); vesting of 8,544 restricted stock units; vesting of 11,785 restricted stock units; vesting of 17,265 stock options ($74.91 exercise price); vesting of 30,147 stock options ($53.6 exercise price).
11/01/2027	Vesting of 9,563 stock options with an exercise price of $52.83.
02/01/2028	Vesting of 12,972 stock options with an exercise price of $68.54.
08/06/2028	Expiration of stock options with an exercise price of $120.46.
08/15/2028	Vesting of performance restricted stock units (70,708 shares) if performance goals are achieved; vesting of 11,784 restricted stock units; vesting of 17,266 stock options ($74.91 exercise price); vesting of 30,147 stock options ($53.6 exercise price).
08/15/2029	Expiration of stock options with an exercise price of $94.52.
08/15/2030	Expiration of performance stock options with an exercise price of $84.61 and stock options with an exercise price of $84.61.
11/01/2030	Expiration of stock options with an exercise price of $52.83.
02/01/2031	Expiration of performance stock options with an exercise price of $68.54 and stock options with an exercise price of $68.54.
08/15/2034	Expiration of stock options with an exercise price of $74.91.
08/15/2035	Expiration of stock options with an exercise price of $53.6.

Recommendation

hold

The filing reports a routine insider transaction where the CEO disposed of shares to cover tax withholding obligations. This is a common practice and does not typically signal a change in the company's fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

BIO-TECHNE, TECH, Kim Kelderman, Form 4, Insider Transaction, Common Stock, Stock Options, Restricted Stock Units, CEO, Director, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.